Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance

View Full Paper
Ask AI
Bookmark
Share

Authors

XJXu JiYBYanliang BaiWQWen Qin

Discussion

Loading...

Member takes

Overview

Observational analysis reports early switch to KPD improves outcomes in myeloma patients experiencing adverse events and suboptimal induction.

Key Points

  • Overall response rate reached 91.23% after early switch to KPD regimen, highlighting its effectiveness.
  • Among 57 myeloma patients, 32 achieved complete response, underscoring the regimen's potential.
  • Analysis conducted across 12 medical centers for patients intolerant to first-line therapies.
  • Switching to KPD may enable deeper remissions while maintaining a manageable safety profile.

Cite This Study

Ji et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e280https://doi.org/10.1182/blood-2025-7548
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025
  2. 2Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.2025
  3. 3Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd2025 · 2 citations
  4. 4Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis2025
  5. 5Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025